A novel loss-of-function mutation of  (p.R299Q) in a Japanese family with Hypoparathyroidism, Deafness, and Renal Dysplasia (HDR) syndrome by unknown
CASE REPORT Open Access
A novel loss-of-function mutation of GATA3
(p.R299Q) in a Japanese family with
Hypoparathyroidism, Deafness, and Renal
Dysplasia (HDR) syndrome
Tetsuji Okawa1, Masanori Yoshida1*, Takeshi Usui2, Takahiro Kudou3, Yasumasa Iwasaki4, Kazuki Fukuoka1,
Norio Takahashi1, Yuka Uehara1 and Yutaka Oiso5
Abstract
Background: Hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome is a rare autosomal dominant
disorder caused by mutations in the zinc finger transcription factor gene, GATA3. GATA3 has 2 zinc finger domains,
which play an important role in the increase in target gene transcription activity.
Case presentation: A 50-year-old woman and her 27-year-old daughter were followed up because of
hypoparathyroidism. They had bilateral sensorineural deafness. Abdominal computed tomography scanning
revealed renal dysplasia in the mother, but no renal anomaly in the daughter. Direct sequencing of GATA3 gene
revealed a novel heterozygous missense mutation at codon 299 (p.R299Q) in exon 4. This mutation is located at the
junction between the 2 zinc fingers. The structure prediction showed that it caused a conformation change in this
junction area, affecting the spatial position of the zinc fingers. Additionally, a more marked conformation change was
observed in the N-terminal zinc finger region compared to that in the C-terminal region. Functional analysis of this
mutant protein using an in vitro luciferase reporter assay system confirmed that the mutation abolished the enhancing
effects of wild-type GATA3 on the promoter activity of the consensus GATA responsive element and that of human
PTH gene.
Conclusion: We identified a novel R299Q mutation in GATA3 in a Japanese family with HDR syndrome. We confirmed
that R299Q is a loss-of-function mutation, due to the extensive conformational change in the zinc fingers of GATA3.
Keywords: Hypoparathyroidism, Deafness, and renal dysplasia (HDR) syndrome, Zinc finger, GATA3, Heterozygous
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Background
Hypoparathyroidism, deafness, and renal dysplasia (HDR)
syndrome is a rare hereditary autosomal dominant dis-
order [1]. Haploinsufficiency of GATA3 gene, located on
chromosome 10p15, is responsible for HDR syndrome
[2, 3]. Human GATA3 consists of 6 exons that span
20 kb of genomic DNA and encode 444 amino acids
[4]. GATA3 is a dual zinc finger transcription factor
that binds to the consensus motif (A/T)GATA(A/G) on
the target gene promoter region [5–7]. This transcrip-
tion factor plays a pivotal role in differentiation in the
parathyroid gland, inner ear, kidney, thymus, and cen-
tral nervous system [8, 9]. Patients with HDR syndrome
mainly present with a triad of clinical symptoms, viz.,
primary hypoparathyroidism, sensorineural deafness,
and renal dysplasia with variable presentation even
within individuals with the same mutation [10, 11]. On
the other hand, GATA3 also serves as a master regula-
tor of the differentiation of T helper type 2 cells [5, 6],
but no immune deficient symptom has been reported
in patients with HDR syndrome.
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Here, we report a novel mutation of GATA3 in a Japanese
family with HDR syndrome, presenting with different
renal phenotypes. We analyzed the 3-dimensional struc-
ture and transcriptional function of this mutant GATA3.
Case presentation
A 50-year-old Japanese woman had been followed up at
our hospital because of hypoparathyroidism. At the age
of 33 years, the patient had suddenly experienced a gen-
eral convulsion with loss of consciousness and was taken
to the emergency room of our hospital. Upon arrival,
she regained consciousness. She was positive for the
Trousseau sign. Blood examination showed severe hypo-
calcemia (5.2 mg/dL) and hyperphosphatemia (4.7 mg/
dL) with a relatively low level of intact PTH (7 pg/mL).
Serum creatinine and blood urea nitrogen levels were
normal (0.6 mg/dL and 9.1 mg/mL, respectively) with
no other electrolyte disorder. Percentage of tubular re-
absorption of phosphate was 98.4 % (reference range:
81–90 %). Anterior pituitary hormone levels and thyroid
and adrenal functions were normal. She was diagnosed
with idiopathic hypoparathyroidism, and calcium lactate
and 1α-hydroxyvitamin D3 treatment were initiated. After
calcium lactate was discontinued, administration of 2 μg
of 1α-hydroxyvitamin D3 was sufficient to maintain her
serum calcium level within the normal range. Head com-
puted tomography (CT) scanning showed severe brain cal-
cification. CT images at the age of 47 years are shown in
Fig. 1a and b; calcification was observed in the bilateral
basal ganglia, thalamus, cerebellum, and deep white matter.
She had mild juvenile cataracts in both eyes. Fluorescence
in situ hybridization did not indicate 22q11.2 syndrome, as
no microdeletion was observed in the 22q11.2 region (data
not shown). Hearing disturbance progressed gradually;
an audiogram performed at the age of 41 years indi-
cated bilateral sensorineural deafness (right: 47 dB, left:
55 dB). Abdominal CT revealed renal dysplasia on the
right side (Fig. 1c). These clinical findings were consist-
ent with HDR syndrome.
This patient’s 27-year-old daughter also had hypopara-
thyroidism, which was incidentally identified when she vis-
ited our hospital for a common cold at the age of 14 years;
blood examination showed hypocalcemia (5.7 mg/dL) and
hyperphosphatemia (6.8 mg/dL) with a low level of intact
PTH (9 pg/mL). Thereafter, she had received 1 μg of 1α-
hydroxyvitamin D3. She had a moderate hearing disturb-
ance (right: 56 dB, left: 47 dB). Unlike her mother, faint
calcifications in the basal ganglia and no renal abnormal-
ities were observed.
Sequencing analysis was performed for all coding re-
gions, including the adjacent intronic regions, of GATA3
from the peripheral blood of the mother. A novel hetero-
zygous p.R299Q (CGG>CAG) missense mutation was
found in exon 4 (Fig. 2). This codon 299 amino acid of
GATA3 was located in the liker region, consisting of 30
amino acids, between 2 consecutive zinc finger domains.
These zinc fingers are important for the increase in the
transcriptional activity of GATA3 target genes.
We analyzed the 3-dimensional structural models of
wild-type (GATA3/WT) and mutant (GATA3/R299Q)
GATA3 using the Sequence to Function Annotation Server
(SFAS) provided by the Protein Data Bank Japan (PDBj:
http://pdbj.org/) [12]. The structure of both proteins was
compared and visualized by UCSF Chimera, developed by
the Resource for Biocomputing, Visualization, and Inform-
atics (RBVI) (http://www.cgl.ucsf.edu/chimera/) [13]. The
protein conformation showing the 2 zinc fingers is pre-
sented in Fig. 3. This mutation altered the spatial position
of the 2 zinc fingers through a conformation change in the
linker between the zinc fingers. A more marked conform-
ational change was observed in the position of the N-
terminal zinc finger (ZnF1; residues 264–288) than in the
C-terminal zinc finger (ZnF2; residues 318–342), probably
because the Arg-299 residue is located near the zinc ion of
ZnF1 (Fig. 3a). The conformational change also extended
into a part of ZnF2. This extensive conformational change
probably affects the biological function of GATA3.
The transcriptional function of GATA3/R299Q was
evaluated using a luciferase reporter assay system. The
transcription activity of pGATA/Luc with a consensus
Fig. 1 Plain head and abdominal computed tomography (CT) scans
of the proband. a, b. Head CT. Severe calcification was observed in
the basal ganglia, thalamus, deep white matter (a), and cerebellum
(b) (arrow). c. Abdominal CT. Renal dysplasia can be seen on the
right side (arrow)
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GATA responsive element significantly increased when
the GATA3/WT expression vector was transfected,
whereas this enhancing effect was completely lost in the
GATA3/R299Q vector-introduced cells (Fig. 4a). This re-
sult indicated that GATA3/R299Q severely affected the
transcription activity of various GATA3-regulated genes.
We next examined the effects of GATA3/WTand GATA3/
R299Q on the promoter activity of the PTH gene. GATA3/
WT overexpression significantly enhanced the transcrip-
tion activity of human PTH in a dose-dependent manner,
whereas this stimulatory effect was not observed with
GATA3/R299Q overexpression (Fig. 4b). These data sug-
gested that the GATA3/R299Q protein failed to increase
the PTH gene expression. The extensive conform-
ational change of GATA3/R299Q most likely reduces
the transcriptional activity of GATA3 target genes asso-
ciated with fetal differentiation of the organs affected
in HDR syndrome, such as the parathyroid gland, inner
ear, and kidney.
Method
Preparation of DNA and sequence analysis
DNA was extracted from peripheral blood leukocytes
using standard methods. All PCR-amplified exons and
splice junctions of GATA3 from the proband were directly
sequenced [14], after permission was obtained from the
patient and the ethical committees of Nagoya Ekisaikai
Hospital and National Hospital Organization Kyoto
Medical Center.
Fig. 2 Direct sequencing of GATA3. Upper panel shows the genomic structure of GATA3, consisting of 6 exons (indicated by boxes). The black and
white boxes denote the coding regions and the untranslated regions, respectively. GATA3 encodes a protein with 2 transactivating domains (TA1 and
TA2) and 2 zinc finger domains (N-terminal zinc finger [ZnF1] and C-terminal zinc finger [ZnF2]). ZnF1 is encoded by exon 4 and ZnF2 is encoded by
exon 5. The arrow indicates the mutation site. The lower panel shows the nucleotide sequences around codon 299 in exon 4 of GATA3
Fig. 3 Three-dimensional structural modeling of wild-type and mutant GATA3 proteins. a, Wild-type GATA3 protein. b, GATA3 mutant protein
(R299Q). c, Merge of (a) and (b). Residues 263–347 are shown. This region includes ZnF1 (residues 264–288) and ZnF2 (residues 318–342). The
arrows indicate residues 263 (N-terminal) and 299. Residues with a significant conformational change by R299Q mutation are color-coded (bright
yellow [wild-type] and green [mutant])
Okawa et al. BMC Endocrine Disorders  (2015) 15:66 Page 3 of 6
Plasmid construction
Full-length human GATA3 cDNA was kindly provided by
RIKEN BioResource Center (Tsukuba, Japan) as a plasmid
[15]. A GATA3 expression vector (GATA3/WT) was con-
structed by insertion of the human GATA3 cDNA into a
pRc/Rous sarcoma virus (RSV) vector (Invitrogen, San
Diego, CA). Specific primers used for PCR were as follows:
forward 5′- GAGGCCATGGAGGTGACGGC-3′, reverse
5′-TCTAACCCATGGCGGTGACC-3′; mutant construct
(GATA3/R299Q) was made from GATA3/WT by a site-
directed mutagenesis technique using the primers as fol-
lows: forward 5′-GGACAGAACCAGCCCCTCATTA-3′,
reverse 5′-TAATGAGGGGCTGGTTCTGTCC-3′. For the
luciferase assay, 2 luciferase reporter plasmids were used:
pGATA/Luc, containing the consensus GATA binding
element (LR-2103, Signosis, Santa Clara, CA), and phPTH/
Luc containing the 5′-promoter region of human PTH
(−2000/+54; +1 designates the transcription start site) [16].
Cell culture and transfection
HepG2 cells were maintained in T75 culture flasks using
DMEM culture medium supplemented with 10 % (v/v)
fetal bovine serum, penicillin (100 U/ml), and strepto-
mycin (100 μg/ml) at 37 °C with 5 % CO2. In each ex-
periment, cells were cultured in 24-well plates, and then
transient transfection was carried out using FuGene 6
reagent (Promega, Madison, WI), 2 μl of FuGene 6 was
used per 1 μg of plasmids (reporter plasmids: 0.5 μg; ex-
pression plasmids: 0.5 μg) for each well. When different
doses of an expression plasmid were used in an experi-
ment, the total amount of transfected plasmid DNA was
kept constant by addition of the empty control vector
(pRc/RSV). Cells were harvested 48 h after the transfec-
tion and a luciferase assay was performed as described
previously [17].
Computer modeling of GATA3 structure
Three-dimensional structural modeling of wild-type and
mutant GATA3 proteins was analyzed using SFAS pro-
vided by PDBj (http://pdbj.org/) [12]. The structural in-
formation of the wild-type GATA3 was derived from
chain A of PDB entry 4hc7. Molecular graphics of the
comparison of protein structures (residues 263–347)
were created by UCSF Chimera which is a program to
display molecular graphics of protein and nucleic acids
developed by RBVI funded by the National Institutes of
Health (http://www.cgl.ucsf.edu/chimera/) [13].
Statistics
Samples in each group of transcription activation experi-
ments were analyzed in triplicate. All of the experiments
were performed more than twice to confirm the reproduci-
bility, and the representative data are shown in the results.
Data are expressed as means ± S.E. The differences between
experimental values were analyzed by Student’s t test.
Statistical analysis was performed using one-way ANOVA.
P-values below 0.05 were considered significant.
Fig. 4 Functional analysis of wild-type and mutant GATA3 proteins using a luciferase reporter assay system. a, Effects of the overexpression of
wild-type and mutant GATA3 on the transcription activity of the heterologous promoter. Mutant GATA3 overexpression abolished the enhancing
effects of wild-type GATA3 on the promoter containing the consensus GATA responsive element (pGATA/Luc). b, Effects of the overexpression of
wild-type and mutant GATA3 on human PTH gene expression. Wild-type GATA3 overexpression significantly enhanced the transcription activity of
human PTH (phPTH/Luc), whereas this stimulatory effect was not observed with mutant GATA3 overexpression. Data are expressed as folds increase
over control group. P < 0.05 vs. corresponding control
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Discussion
In the present case, we identified a novel heterozygous
missense mutation of GATA3 in a Japanese family affected
with HDR syndrome. This R299Q mutation induced an
orientation change of the 2 zinc fingers and abolished its
physiological function as a transcription factor.
The clinical manifestation of HDR syndrome is hetero-
geneous [3]. A triad of HDR symptoms is observed in
62.3 % of patients; 28.6 % of patients show only hypopara-
thyroidism and deafness, and 2.6 % of patients show only
deafness and renal disease [18]. Hypoparathyroidism and
hearing loss is the most common combination. Many dif-
ferent renal anomalies, with variable penetrance, are ob-
served, including renal dysplasia, hypoplasia, aplasia, and
vesico-ureteral reflux [3, 10, 11]. In addition, similar to our
case, patients with HDR syndrome present with heteroge-
neous clinical manifestation even among individuals
having the same mutation [10, 11]. The mechanism of het-
erogeneous symptoms has not been fully elucidated. In
animal study, Grote et al. showed that the nephric duct-
specific inactivation of Gata3 leads to a wide spectrum of
urogenital malformations through the glial cell line-
derived neurotrophic factor/Ret signaling pathway [19].
Gata3 prevents ectopic ureter budding and premature dif-
ferentiation of nephric duct cells. On the other hand,
Gata3, which is also expressed in spiral ganglion neurons
throughout their development, is essential for formation of
the intricately patterned connections in the cochlea [20].
GATA3 belongs to a family of dual zinc finger transcrip-
tion factors. Zinc fingers of the mammalian GATA proteins
(GATA 1–6) have a Cys-X2-Cys-×17-Cys-X2-Cys structure
(with X representing any amino acid residue), in which a
single zinc ion is coordinated by 4 cysteine residues [7]. Its
tertiary structure reveals 2 anti-parallel β-sheets, an α-
helix, and a long loop. The α-helix binds into the major
groove of DNA. In GATA3, ZnF2 is essential to the bind-
ing of the transcription factor to the consensus sequence
(A/T)GATA(A/G) on the target gene promoter region,
whereas ZnF1 is thought to stabilize this binding through
its interaction with another cofactor, Friends of GATA
(FOG) 2 [21, 22].
In this study, the 3-dimensional conformation of wild-
type and mutant GATA3 was analyzed using SFAS, which
runs several external programs for sequence alignment and
structural modeling and organizes their results. Protein
structure comparison was presented using another web ap-
plication, UCSF Chimera, to construct high-resolution im-
ages. The structure of residues 263–347, ranging from
ZnF1 to ZnF2, is displayed in Fig. 3. The configuration of
the linker between the zinc fingers was affected severely by
the mutation R299Q, which is located between the 2 zinc
fingers. In addition, the mutation created a greater con-
formational change in ZnF1 than in ZnF2, probably
because Arg-299 is located near the zinc ion of ZnF1. This
Arg residue may stabilize a coordinate bond between the
zinc ion and Cys residues, which are the crucial compo-
nents of ZnF1. Substituting the basic amino acid (Arg) with
neutral amino acid (Gln) may affect this stabilization and
cause a change in the orientation in the protein structure.
Furthermore, this conformational change spread into
ZnF2. These results suggest that R299Q mutation impairs
the function of both ZnF1 and ZnF2.
To date, the conformation of GATA3 mutant proteins
has been investigated only in 3 cases of HDR syndrome
[10, 11, 23]. Gaynor et al. showed that Thr272Ile, located
in ZnF1, resulted in the loss of a polar side chain inter-
action between Thr-272 and Leu-274 [23]. This muta-
tion changed the ZnF1 structure, leading to loss of DNA
binding and FOG2 interactions. Ali et al. also showed
that Leu348Arg could alter the transcriptional activity of
GATA3 because of the substitution of a non-polar
hydrophobic Leu residue for a positively charged Arg
residue; this Leu 348 residue is located in ZnF2 and lies
at the end of an α-helix which makes contact with DNA
at the DNA major groove within the GATA motif of the
promoter region [10]. Moreover, Chiu et al. analyzed the
conformation change caused by Arg353Ser, which is lo-
cated at the C-terminal DNA-binding region following
ZnF2 (residues 318–342), using NNPredict software.
This mutation was predicted to disrupt the helix turn
composed of residues 355–358, because of the substitu-
tion of a basic for a polar, uncharged residue, which
changed the angle between ZnF2 and the adjacent C-
terminal tail [11]. However, our case is the first report of
a conformation change caused by a mutation at the
junction between the 2 zinc fingers; the amino acid sub-
stitution affected the conformation of both Zn fingers.
Structure prediction model obtained by PDBj provides
useful information about GATA3 mutant. Amino acids
are classified into 4 groups such as nonpolar, polar, acidic,
and basic amino acids. Substitution between amino acids
belonging to different groups is likely to cause critical con-
formation change.
We also confirmed that R299Q was a loss-of-function
mutation using an in vitro reporter assay system. GATA3/
R299Q overexpression failed to increase the transcription
activity of the GATA responsive element. In addition, our
data showed that GATA3/WT activated PTH transcrip-
tional activity, whereas GATA3/R299Q did not (Fig. 4b).
This result is of interest, as there has been no previous dir-
ect evidence that GATA3 is a positive regulator of PTH
expression. The consensus GATA3 binding element is not
present in the 5′-promoter region of human PTH, sug-
gesting that the observed enhancing effect of GATA3 is
caused by an indirect pathway, rather than by the direct
binding of GATA3. Further investigations are required to
elucidate this molecular mechanism. Our results suggest
that GATA3 plays an important role not only in the
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development of the parathyroid gland in fetus, but also in
PTH regulation after birth.
Conclusion
In this study, we identified a novel heterozygous missense
mutation of GATA3 in a Japanese family with HDR syn-
drome. We confirmed that the R299Q mutant is a loss-of-
function mutation causing an extensive conformational
change of 2 zinc fingers.
Consent
Written informed consent was obtained from both pa-
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